Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Increasing Retention in Methadone Maintenance Treatment: Feasibility and Preliminary Efficacy of Ketamine for the Treatment of Patients With OUD and Comorbid Depression (OUDCD)


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05051449

Organisation Name: University of Maryland, Baltimore

Overal Status: Not yet recruiting

Start Date: February 2022

Last Update: September 28, 2021

Lead Sponsor: University of Maryland, Baltimore

Brief Summary: Methadone is a first-line, evidence-based treatment for opioid use disorder (OUD). Unfortunately, retention and adherence in methadone treatment is a major challenge. OUD patients frequently present with co-morbid depression (OUDCD), a risk factor for poor OUD treatment outcomes, overdose, and suicide. The last two decades have seen an exciting and transformational development in the treatment of depression - ketamine. As a safe, rapid-acting anti-depressant deliverable within the context of methadone maintenance treatment, ketamine could feasibly change the landscape of treatment for OUD patients with comorbid depression. This proposal seeks to evaluate implementation outcomes (feasibility and patient acceptance) as well as preliminary efficacy of ketamine on methadone treatment outcomes for OUD patients (n=6) with comorbid depression and depressive symptoms presenting for methadone treatment.

Conditions:
  • Opioid-use Disorder
  • Depressive Disorder


Total execution time in seconds: 0.2439649105072